Ironwood Pharmaceuticals, Inc.

Forest Laboratories Holdings Limited

Yun Mo

Mahendra G Dedhiya

Angelika Fretzen

Brian Cali

Steven Richard Witowski

Alfredo Grossi

Hong Zhao

Mark G Currie

Ahmad Hashash

Anil Chhettry

Matthew Ronsheim

Andreas Grill

Ritesh Sanghvi

Matthew Miller

Mohammad Mafruhul Bari

Joseph Stainkamp

Mahendra Dedihiya

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

Stable formulations of linaclotide

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

Linaclotide compositions

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ('linaclotide'; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.

Formulations comprising linaclotide

Growing community of inventors

Commack, NY, United States of America

Yun Mo